Understanding SLC6A3 Mutations and Dopamine Transporter Deficiency Syndrome (DTDS)
If you or a loved one has recently been told they have an SLC6A3 mutation, you're likely searching for answers. Learning about a rare genetic condition can feel overwhelming, especially when information is limited.
The SLC6A3 gene provides instructions for making the dopamine transporter (DAT), a protein that helps regulate dopamine—a chemical messenger essential for movement, learning, behavior, and many other brain functions.
When disease-causing (pathogenic) changes occur in both copies of the SLC6A3 gene, they can lead to Dopamine Transporter Deficiency Syndrome (DTDS), also known as DAT deficiency. DTDS is an ultra-rare inherited neurological disorder that primarily affects movement and development.
What Is the SLC6A3 Gene?
The SLC6A3 gene contains the instructions for producing the dopamine transporter, sometimes abbreviated as DAT. After dopamine is released between nerve cells, the dopamine transporter recycles it so it can be used again.
This recycling process is essential for normal communication between brain cells.
When the dopamine transporter does not function properly because of pathogenic variants in the SLC6A3 gene, dopamine signaling becomes disrupted, contributing to the symptoms seen in DTDS.
What Is an SLC6A3 Mutation?
A mutation (also called a genetic variant) is a change in a gene's DNA sequence.
Not every SLC6A3 variant causes disease. Some variants are harmless, while others affect how well the dopamine transporter functions.
Most individuals diagnosed with Dopamine Transporter Deficiency Syndrome inherit two disease-causing SLC6A3 variants—one from each parent. This inheritance pattern is known as autosomal recessive inheritance.
Signs and Symptoms of SLC6A3-Related DTDS
Symptoms vary from person to person but commonly include:
Developmental delay
Dystonia (involuntary muscle contractions)
Parkinsonism
Bradykinesia (slowed movement)
Rigidity
Feeding difficulties
Delayed motor milestones
Speech and communication challenges
Eye movement abnormalities
Sleep disturbances
Because these symptoms overlap with other neurological conditions, many children are initially diagnosed with cerebral palsy, epilepsy, or another movement disorder before receiving a genetic diagnosis.
How Is an SLC6A3 Mutation Diagnosed?
Most individuals are diagnosed through genetic testing, such as:
Whole exome sequencing (WES)
Whole genome sequencing (WGS)
Targeted genetic testing
Multi-gene panels for movement disorders
A clinical geneticist or neurologist can help interpret genetic testing results and determine whether identified SLC6A3 variants are disease-causing.
Is There a Cure?
At present, there is no cure for Dopamine Transporter Deficiency Syndrome.
Treatment focuses on managing symptoms through a multidisciplinary care team that may include neurologists, physical therapists, occupational therapists, speech-language pathologists, nutrition specialists, pulmonologists, gastroenterologists, orthopedic providers, and palliative care specialists.
Researchers around the world are actively investigating potential treatments, including gene therapy, disease modeling, and drug repurposing, offering hope for future advances.
Finding Support After an SLC6A3 Diagnosis
Receiving a diagnosis of an SLC6A3-related disorder can feel isolating, but you are not alone.
The DTDS Foundation is dedicated to supporting individuals and families affected by Dopamine Transporter Deficiency Syndrome (DTDS) through education, advocacy, family support, and research initiatives. Whether you've just received genetic test results or have been living with DTDS for years, our community is here to help.
Explore our educational resources, read family stories, and learn how you can get involved as we work together toward better treatments—and ultimately, a cure.
Learn More
You may also find these DTDS Foundation resources helpful: